The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …

Uncommon epidermal growth factor receptor (EGFR) mutations collectively account for 10%
of EGFR mutations, harboring heterogeneous molecular alterations within exons 18–21 with …

Introduction Limited clinical data are available regarding the efficacy of EGFR tyrosine
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …

While randomized controlled trials (RCTs) are the gold standard for evidence-based
medicine, they do not always reflect real-world patient populations, limiting their …

The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …

Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy
has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which …

While the development of EGFR-targeted tyrosine kinase inhibitors (TKIs) has revolutionized
treatment of EGFR mutation-positive non-small-cell lung cancer, acquired resistance to …

The majority of epidermal growth factor receptor (EGFR) mutations (85–90%) are exon 19
deletions and L858R point mutations of exon 21, characterized by high sensitivity to EGFR …

Purpose: The advent of next-generation sequencing technologies has enabled the
identification of several activating mutations of Erb-B2 receptor tyrosine kinase 2 (ERBB2) …

Personalized medicine has emerged as the future of cancer care to ensure that patients
receive individualized treatment specific to their needs. In order to provide such care …